US 10,889,650 B2
Agent, uses and methods for treatment
Lars Christian Biilmann Rønn, Valby (DK); Ibrahim John Malik, Valby (DK); Jeffrey B. Stavenhagen, Valby (DK); Søren Christensen, Valby (DK); Jan Egebjerg, Valby (DK); Arnout Gerritsen, Utrecht (NL); Edward van den Brink, Utrecht (NL); Paul Parren, Utrecht (NL); and Rob de Jong, Utrecht (NL)
Assigned to H. Lundbeck A/S, Valby (DK)
Filed by H. Lundbeck A/S, Valby (DK)
Filed on Jul. 24, 2019, as Appl. No. 16/521,279.
Application 16/521,279 is a continuation of application No. 15/743,549, granted, now 10,479,835, previously published as PCT/EP2016/066516, filed on Jul. 12, 2016.
Claims priority of application No. 1512215.3 (GB), filed on Jul. 13, 2015.
Prior Publication US 2020/0190188 A1, Jun. 18, 2020
Int. Cl. C07K 16/00 (2006.01); A61K 51/10 (2006.01); C07K 16/28 (2006.01); A61P 25/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/286 (2013.01) [A61K 39/3955 (2013.01); A61P 25/28 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
OG exemplary drawing
 
1. An antibody, or an antigen-binding fragment thereof, comprising:
a) a light chain variable domain L-CDR1 comprising SEQ ID NO: 49;
b) a light chain variable domain L-CDR 2 comprising SEQ ID NO: 50;
c) a light chain variable domain L-CDR 3 comprising SEQ ID NO: 51;
d) a heavy chain variable domain H-CDR 1 comprising SEQ ID NO: 52;
e) a heavy chain variable domain H-CDR 2 comprising SEQ ID NO: 53 and
f) a heavy chain variable domain H-CDR 3 comprising SEQ ID NO: 54.